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Abstract
Background: Midkine (MK), a member of the heparin-binding growth factor family, which includes MK and 
pleiotrophin, is known to possess neurotrophic and neuroprotective properties in the central nervous system. Previous 
studies have shown that MK is an effective neuroprotective agent in reducing retinal degeneration caused by excessive 
light and decreasing hippocampal neuronal death in ischemic gerbil brain. The present study was undertaken to 
investigate whether MK acts as an anticonvulsant in kainic acid (KA)-induced seizure in mouse and blocks KA-mediated 
neuronal cell death in hippocampus.
Results: Increased expression of MK was found in hippocampus of mouse following seizures induced by 
intracerebroventricular injection of KA, and MK expression was found in glial fibrillary acidic protein (GFAP)-positive 
astrocytes. Concurrent injection of MK and KA attenuated KA-induced seizure activity and cell death of hippocampal 
neurons including pyramidal cells and glutamic acid decarboxylase 67 (GAD67)-positive GABAergic interneurons in the 
CA3 and hilar area.
Conclusion: The results of the present study indicate that MK functions as an anticonvulsant and neuroprotective 
agent in hippocampus during KA-induced seizures.
Background
Temporal lobe epilepsy (TLE) is pathologically character-
ized by extensive neuronal loss in the CA1, CA3 and hilar
regions of hippocampus [1,2]. Previous studies have dem-
onstrated that the animal models of TLE generated by
intracerebroventricular injection of kainic acid (KA)
faithfully reproduce clinical and pathological features
found in human TLE [3-7].
Previous studies have reported the possible involve-
ment of neurotrophic factors in epilepsy as suggested by
the gene expression of neurotrophic factors such as NGF,
BDNF and NT-3 in hippocampus in human TLE as well
as in TLE animal models [8,9]. Midkine (MK), one of such
neurotrophic factors, has emerged as an important neu-
romodulator in the central nervous system (CNS). MK, a
member of the heparin-binding growth factor family,
which includes MK and pleiotrophin, is known to possess
neurotrophic and neuroprotective properties [10,11]. MK
was originally isolated as the product of retinoic acid-
responsive gene that functions primarily in inducing cell
differentiation in mouse teratocarcinoma cells [12], and
has the ability to influence a variety of neuronal functions
including neurite extension [13], neuronal differentiation
[14,15] and neuronal survival following injury or damage
in the CNS [15,16]. During the fetal development of the
CNS, MK expression was demonstrated in neuroepithe-
lial/neural progenitor cells following ethylnitrosourea
injury [17] indicating that MK might have a role in cellu-
lar proliferation [18]. Recent studies further showed that
MK has been implicated in neurological diseases, includ-
ing Alzheimer's disease [19], cerebral ischemia [20] and
Parkinson-dementia complex of Guam (Lytico-bodig dis-
ease) [21]. In patients with Alzheimer's disease [19] or
Lytico-bodig disease [21], MK immunoreactivity was
found in senile plaques and neurofibrillary tangles. In
addition, an increased expression of MK was found in
astrocytes in rat models of cerebral ischemia [22]. It is not
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known, however, whether the expression of MK in the
brain after the brain injury is a part of an endogenous
repair process to prevent further damage in the CNS.
The objectives of the present study are to determine
whether intracerebroventricularly injected MK acts as an
anticonvulsant and blocks KA-mediated neuronal cell
death in hippocampus.
Results
MK expression after seizures
We first examined MK expression immunohistochemi-
cally in mouse hippocampus following KA injection.
Injection of KA (0.2 μg/mouse) to mice induced severe
epileptiform seizures (mean score 4.2/maximum score
5.0). Basal level of MK immunoreactivity was found in
hippocampal pyramidal neurons in control mouse brain
injected with vehicle [phosphate-buffered saline (PBS)]
(Figure 1A, top left panel), while in mouse injected with
KA decreased MK expression was detected in pyramidal
neurons (Figure 1A, bottom left panel; see arrows); Nissl
staining of the adjacent sections confirmed that the cellu-
lar area of decreased MK immunoreactivity was associ-
ated with damaged pyramidal neurons (Figure 1A,
bottom right panel; see arrows). Nissl staining in control
animals receiving PBS injection showed no evident neu-
ronal damage (Figure 1A, top right panel).
Interestingly, we have found the number of MK-posi-
tive cells markedly increased in stratum lacunosum
moleculare (Slm) area of CA3 at 24-hr post-KA injection
relative to PBS controls. Representative MK immunos-
taining in CA3 Slm is shown in Figure 1B (box denotes
area of high magnification, top panel). In PBS-injected
brain, only small number of MK-positive cells was
observed (Figure 1B, middle panel). Following injection
of KA, CA3 Slm area demonstrated an increase in the
number of MK-positive cells (Figure 1B, bottom panel).
Double-labeling immunofluorescence staining was then
used to investigate MK expression in glial cells in KA-
injected hippocampus. Representative double staining for
MK (green staining, Figure 1C top panel) and GFAP (red
staining, Figure 1C middle panel) showed that MK was
expressed in GFAP-positive astrocytes; there was no MK
expression in anti-complement receptor 3 (OX-42)-posi-
tive microglia (data not shown).
Q u a n t i f i c a t i o n  o f  M K  e x p r e s s i o n  d a t a  ( e x p r e s s e d  a s
area density of MK-positive cells, Figure 2) showed that
KA injection significantly decreased MK immunoreactiv-
i ty  by 44% i n S P a r ea  r e la t ive  t o PBS-in ject ed c on tr ol .
However, the MK immunoreactivity in animals with KA
injection markedly increased by 651% in Slm area as
compared to PBS-injected control.
Anticonvulsant effect of MK
To further investigate the role of MK in KA-injected hip-
pocampus, we examined the potential protective effects
o f  M K  a g a i n s t  KA - i n d u c e d  s e i z u r e s  a n d  n e u r o t o x i c i t y .
Seizure onset was approximately 170 sec following KA
injection, which lasted for mean 1,200 sec (Table 1). The
intensity of seizures reached mean score 4.2 (maximum
score 5.0) when the seizure activity was highest (5-10 min
Figure 1 MK expression in the hippocampus after KA injection. 
(A) Representative immunofluorescence images of MK immunoreac-
tivity in hippocampal CA3 pyramidal neurons 24 hr after PBS injection 
(top left panel) or KA (0.2 μg/mouse, bottom left panel). Adjacent hip-
pocampal sections stained with Nissl staining (right panels) are shown 
here. Following KA treatment, cell death in CA3 pyramidal neurons is 
clearly visible (arrows). Scale bars: 20 μm (top panels), 30 μm (bottom 
panels). (B) Representative immunofluorescence images of MK-posi-
tive cells in CA3 Slm (striatum lacunosum moleculare) (box in top pan-
el indicates region of interest) after injection with PBS (middle panel) or 
KA (0.2 μg/mouse, bottom panel). (C) Double-labeling immunofluores-
cence staining of MK (green, top panel) with GFAP (red, middle panel) 
showing MK immunoreactivity is co-localized on GFAP-positive astro-
cytes in CA3 Slm (bottom panel). Scale bar: 20 μm.Kim et al. BMC Neuroscience 2010, 11:42
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after KA challenge). Interestingly, seizure duration and
intensity were markedly reduced by co-administration of
MK in a dose-dependent manner, although the time of
onset time slightly delayed at a high dose (0.4 μg/mouse).
Seizure duration and intensity were shortened and atten-
uated to 51.4 - 26.5% and 59.5 - 40.5% of the control levels
by treatment with KA (0.1 - 0.4 μg/mouse), respectively.
Neuroprotective effect of MK
Representative Nissl staining 24 hr following KA injec-
tion showed considerable neuronal loss in the hippocam-
pal subregions, CA3 and hilus of the dentate gyrus as
compared to PBS control (Figure 3A, left and middle pan-
els). MK treatment was effective in reducing neuronal
loss in KA-injected hippocampus as shown in a represen-
tative finding in a high dose (0.4 μg/mouse) group (Figure
3A, right panels). The extent of degeneration of hip-
pocampal neurons was quantified in hippocampal subre-
gions, CA1, CA3, and hilus (Figure 3B). The number of
hippocampal neurons was significantly reduced in CA3 (-
81%) and hilus (-85%) by KA exposure, whereas CA1
region (-19%) was relatively spared when compared with
PBS control. Co-application of MK increased survival of
neurons in KA-injected hippocampus in a dose-depen-
dent manner, leading to significant improvements at KA
doses of 0.2 and 0.4 μg/mouse.
Next we investigated the efficacy of MK to block the
KA-induced cell death of GABAergic interneurons
(GAD67-positive neurons). A previous study has
reported that GAD67-positive interneurons are lost in
the hippocampus in KA-injected animal model of excito-
toxicity [23]. Animals receiving KA injection showed sig-
nificant reduction in the number of GAD67-positive
interneurons in subfields of CA1 (strata oriens -80%,
strata pyramidale -64%, strata radiatum -33%), CA3
(strata oriens -91%, strata pyramidale -78%, strata radia-
tum -62%) and layers of dentate gyrus (molecular layer -
37%, granule cell layer -69%, dentate hilus -77%) as com-
pared to PBS control (Figures 4 and 5). Administration of
MK (0.4 μg/mouse) reduced the cell loss in GAD67-posi-
tive neurons caused by KA injection and this neuropro-
tective effect of MK was evident in the subfields of CA3
and layers of dentate gyrus (Figure 4). Application of MK
markedly increased survival of GAD67-positive neurons
in the strata pyramidale (68% improvement), radiatum
(45% improvement) of CA3 and molecular layer (27%
improvement), granule cell layer (29% improvement), and
dentate hilus (33% improvement) of dentate gyrus,
whereas neurons in subfields of CA1 was not effectively
preserved (Figure 5).
Discussion
The main finding of this study is that intracerebroventric-
ular administration of MK conferred neuroprotection
against KA-induced excitotoxic cell death of hippocam-
pal neurons. Our results also demonstrated that MK was
effective in attenuating KA-induced seizures and degen-
eration of GABAergic interneurons in hippocampus. The
results from immunohistochemical staining showed that
damaged pyramidal neurons in hippocampus are corre-
Figure 2 Site-selective MK expression in the KA-damaged hip-
pocampus. Bar graph shows the quantification of MK immunoreactiv-
ity in SP (stratum pyramidale) and Slm (stratum lacunosum 
moleculare) of hippocampal CA3 region 24 hr after PBS or KA (0.2 μg/
mouse) injection. Data are presented as mean ± SEM. * p < 0.05, as 
compared with PBS. One-way ANOVA, Student-Newman-Keuls multi-
ple comparison test.
Table 1: Effects of MK on KA-induced seizure activities
Treatment
(μg/mouse)
Latency to onset
(sec)
Seizure duration
(sec)
Seizure intensity
(maximum score 5.0)
Vehicle 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
KA (0.2) alone 169.9 ± 38.8* 1,200.6 ± 372.3* 4.2 ± 0.1*
+MK (0.1) 160.0 ± 28.5 616.7 ± 50.3# 2.5 ± 0.3#
+MK (0.2) 172.8 ± 33.8 422.4 ± 71.5# 2.2 ± 0.2#
+MK (0.4) 188.8 ± 47.0 318.6 ± 31.7# 1.7 ± 0.3#
Data are presented as mean ± SEM. * p < 0.05, as compared with PBS. # p < 0.05, as compared with KA. Student's t-test.Kim et al. BMC Neuroscience 2010, 11:42
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lated with the decreased level of MK expression (Figure
1A). At present, it is not known whether this reduced
level of MK immunoreactivity in neurons is causative fac-
tor for neuronal degeneration induced by KA injection.
However, previous in vivo studies have demonstrated that
MK is an effective neuroprotective agent in reducing reti-
nal degeneration caused by excessive light [24] and
decreasing hippocampal neuronal death in ischemic ger-
bil brain [25]. Furthermore, MK knock-out mice dis-
played altered expression of calcium-binding protein in
hippocampus and defective working memory [26]. In
view of these observations, it is possible that MK is
involved in the regulation of endogenous neuroprotective
process against externally applied injury or disease.
We have found that the level of MK immunoreactivity
markedly increased in astrocytes after KA injection (Fig-
ure 1C). In a previous report, we have demonstrated
rapid activation of astrocytes in hippocampal alveus and
fimbria, strata oriens and lacunosum moleculare as well
as dentate hilus as early as 1 hr following diisopropyl fluo-
rophosphate (DFP)-induced seizures and neuronal injury
[27]. These observations suggest that the activated astro-
cytes serve as an important source of MK in response to
excitotoxicity. Important findings in the present study are
therapeutic and neuroprotective effects of MK on KA-
induced neuronal injury in CA3 and dentate hilus of hip-
pocampus (Figure 3). Our results are in good agreement
with a previous study of neuroprotective effect of MK in
transient forebrain ischemia when given immediately
before middle cerebral artery occlusion [25]. Previous
studies have demonstrated that KA-injected brain show
dramatic reduction in the number of GAD-positive
interneurons [7,23,28], even in CA1 statum oriens and
alveus where pyramidal neurons are relatively spared
[Figures 3-5][29], which can cause abnormal functional
inhibition of neuronal circuitry leading to hippocampal
hyperexcitability [2,7]. Thus, it is noteworthy that icv
application of MK blocks the degeneration of GAD67-
positive interneurons, especially in the stratum pyrami-
dale and radiatum of CA3, and the molecular layer, gran-
ule cell layer and hilus of dentate gyrus as caused by KA
injection (Figures 4 and 5).
Figure 3 Effect of MK on hippocampal neuronal damage induced 
by KA injection. (A) Representative Nissl-stained sections from ani-
mals 24 hr after PBS (left panels), KA (0.2 μg/mouse, middle panels) or 
KA plus MK (0.4 μg/mouse, right panels) injection. Top panels shows at 
low magnification of the hippocampus. Scale bar: 400 μm. Middle and 
bottom panels show at high magnification of CA3 and dentate gyrus 
(DG) subregions of hippocampus. Scale bars: 200 μm. Note that the 
damaged areas induced by KA are indicated by absence of Nissl-posi-
tive neurons. (B) Quantification of undamaged Nissl-positive neurons 
for the hippocampal subregions CA1 and CA3, and hilus of dentate 
gyrus with different MK doses (0.1 -- 0.4 μg/mouse). Data are presented 
as mean ± SEM. * p < 0.05, as compared with PBS. # p < 0.05, as com-
pared with KA. One-way ANOVA, Student-Newman-Keuls multiple 
comparison test.
Figure 4 Protective effect of MK on KA-induced cell loss of 
GAD67-positive GABAergic neurons. Hippocampal coronal sections 
from animals were immunostained with glutamic acid decarboxylase 
67 (GAD67) antibody 24 hr after PBS (left panels), KA (0.2 μg/mouse, 
middle panels), KA plus MK (0.4 μg/mouse, right panels) injection. High 
magnification of representative GAD67-stained images of hippocam-
pal subregions CA1 (top panels), CA3 (middle panels), and DG (bottom 
panels) from different treatments are shown here. Scale bar: 200 μm. 
Note the paucity of GAD67-positve cells in KA-treated CA3 and dentate 
gyrus subregions.Kim et al. BMC Neuroscience 2010, 11:42
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The majority of the animals experienced stage 4/5 sei-
zure severity after KA injection. A previous study has
demonstrated in KA-injected rat epilepsy model that
dizocilpine (MK-801) inhibited hippocampal neuronal
loss without blocking seizure development [30]. In addi-
tion, several studies in animal model of TLE have also
shown that significant neuronal loss is not necessarily a
prerequisite for the development of seizures [31,32]. Such
results imply that the mechanism of MK action in TLE
model is different from that of MK-801, an NMDA antag-
onist. Our results show that MK-induced neuroprotec-
tion against KA toxicity is primarily associated with
moderation of seizure activity (Table 1). It is believed that
MK plays a role as an anticonvulsant directly (Table 1) or
indirectly by preserving an inhibitory amino acid (GABA)
system including GAD67-positive interneurons (Figures
4 and 5). Furthermore, it is possible to speculate that MK
could be a neurotrophic factor, especially for GAD67-
positive interneurons or astrocytes expressing high levels
of MK (Figure 1) which may contribute to early cessation
of seizure and control of its recurrence.
The exact mechanism of the neuroprotective activity of
MK remains to be further clarified but activation of gene
product(s) associated with apoptosis by MK may provide
some answers. For instance, previous studies have shown
that MK inhibits apoptotic process by up-regulation of
bcl-2 expression [33] and by inhibition of caspase-3 acti-
vation [34]. Thus, it is possible that the MK-mediated
neuroprotective mechanism involves activation of signal
transduction pathways involved in regulation of apop-
totic cell death.
Conclusions
The results of the present study demonstrate that the
administration of MK produces a significant neuropro-
tective effect against KA-induced neuronal loss in mouse
model of epilepsy. Additional studies of MK to elucidate
their neuroprotective activity in animal models of brain
injury and neurodegeneration such as Parkinson's dis-
ease, Huntington's disease, amyotropic lateral sclerosis,
stroke or spinal cord injury should prove MK as a mem-
ber of neurotrophic factors that are valuable in providing
effective treatment for patients with various neurological
disorders.
Methods
Treatment and seizure monitoring
Male C57BL/6 mice (n = 8/group) weighing 25 - 30 g
were used for the experiments. The animals were housed
in a temperature- and humidity-controlled room that was
kept on an alternating 2-hr light/dark schedule. Food and
water were available ad libitum throughout the experi-
ments. All animal experiments were conducted in accor-
dance with the on Animal Care Committee of the
University of British Columbia.
Animals were anesthetized with intraperitoneal injec-
tion of chloral hydrate (7%, 0.1 mL/kg) and then mounted
in a stereotaxic apparatus (David Kopf Instruments,
Tujunga, CA). KA (0.2 μg/0.4 μL PBS/mouse; Sigma, St.
Figure 5 Protective effect of MK on KA-induced GABAergic neu-
ronal cell death. Numbers of GAD67+ neurons were counted in sub-
regions of hippocampus from PBS, KA (0.2 μg/mouse), and KA plus MK 
(0.4 μg/mouse)-injected mice; strata oriens (SO), pyramidale (SP) and 
radiatum (SR) of CA1 (A) and CA3 (B) and all layers of dentate gyrus (C) 
(ML; molecular layer, GCL; granule cell layer, DH; dentate hilus). Data 
are presented as mean ± SEM. * p < 0.05, as compared with PBS. # p < 
0.05, as compared with KA. One-way ANOVA, Student-Newman-Keuls 
multiple comparison test.Kim et al. BMC Neuroscience 2010, 11:42
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Louis, MO) was injected into the right lateral cerebroven-
tricle at the coordinate (AP, -2.0; ML, -2.9; DV, -3.8) using
a 10 μL Hamilton syringe fitted with 26G needle at a rate
of 0.1 μL/min. The needle was left in place for 5 min. MK
(0.1, 0.2 or 0.4 μg/0.4 μL PBS; LG Biotech, Daejon, Korea)
was unilaterally co-injected with KA into the right lateral
cerebroventricle. For sham-operated animals, the same
volume of 0.1 M PBS was stereotaxically injected into the
same coordinates described above. Wounds were
sutured, and animals were allowed to recover and then
returned to their cages. After KA injection, each animal
was placed in a Plexiglas cylinder and their seizure behav-
iors - latency to onset, duration, and intensity - were
recorded for a period of 120 min in a blind manner. Sei-
zure intensity was scored with a slight modification from
a previous scoring system [35] as followed: stage 1,
immobilization and staring; stage 2, head nodding; stage
3, rearing accompanied by forelimb clonus and wet dog
shakes; stage 4, falling and wobbling; stage 5, jumping,
circling, or rolling. The starting time of head nodding was
considered onset time of seizures, because the starting of
immobilization and staring behaviors (stage 1) was not
clear.
Immunohistochemistry
The animals were anesthetized and transcardially per-
fused with 50 mL cold saline followed by 100 mL of 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) 24
hr after KA administration. The brains were removed
from the skull and post-fixed in 4% paraformaldehyde for
24 hr, followed with cryoprotection in 30% sucrose in
phosphate buffer for 2 days. Serial coronal sections at 30
μm were prepared on a cryostat (CM 1900; Leica, Heer-
brugg, Switzerland). Free-floating sections were prepared
from the brains of PBS, KA, and KA plus MK-injected
mice. For single immunofluorescence staining, brain sec-
tions were incubated in PBS containing 5% normal goat
serum and 0.2% Triton X-100 for 30 min at room temper-
ature (RT), and then incubated overnight with rabbit
anti-MK antibody (1:500, kindly provided by Dr. T. Mura-
matsu, Nagoya University, Japan). Sections were then
incubated with Alexa Fluor 488-conjugated goat anti-rab-
bit IgG (1:200; Molecular Probes, Eugene, OR) at RT for 2
hr in the dark. Sections were washed in phosphate buffer,
mounted on slides. Nissl staining was also performed on
slide-mounted brain sections with 0.1% cresyl violet
(Sigma) for the evaluation of hippocampal neuronal loss.
For GAD67 immunohistochemical staining, all incuba-
tion solutions did not contain Triton X-100. The brain
sections were briefly quenched with 3% H2O2 in PBS for
10 min and incubated with 5% normal goat serum for 30
min. The sections were incubated overnight at 4°C with
rabbit anti-GAD67 (1:1000; Chemicon, Temecula, CA).
The sections were then incubated for 1 hr with biotiny-
lated anti-rabbit IgG (1:200; Vector, Burlingame, CA), fol-
lowed by incubation with avidin-biotin complex (1:200,
Vector) for 1 hr and then visualized with 0.05% 3,3'-
diaminobenzidine (Sigma) and 0.003% H2O2. Negative
control sections were prepared for immunohistochemical
staining in an identical manner except the primary anti-
bodies were omitted.
Double-labeling immunofluorescence microscopy
Free floating sections were incubated in PBS containing
3% normal goat serum and 0.3% Triton X-100 for 30 min
at room temperature (RT). Brain sections were incubated
for 48 hr at 4°C in a mixture of two primary antibodies:
MK (1:100) in combination with mouse anti-GFAP
(1:500; Sigma) or mouse OX-42 (1:200; Serotec, Oxford,
UK). Sections were then incubated in a mixture of Alexa
Fluor 488-conjugated goat anti-rabbit IgG (1:200; Molec-
ular Probes) and Alexa Fluor 594-conjugated goat anti-
mouse IgG (1:200; Molecular Probes) at RT for 2 hr in the
dark. Processed sections were mounted on gelatin-coated
slides, coversliped and examined under a Zeiss Axioplan-
2 microscope.
Quantitative analysis
Five coronal hippocampal sections (at the level of the
injection site and spaced 60 μm from each other) were
used for immunohistochemical analysis. All quantitative
analyses were performed in a blind manner. To ensure
consistency in tissue sampling, matched hippocampal
sections (based on anatomical landmark) were always
processed throughout the experiments. Digitized images
of stained sections were acquired using a Zeiss Axioplan-
2 microscope equipped with a DVC camera (Diagnostic
Instruments, Sterling Heights, MI). These images were
then analyzed using Northern Eclipse software (Empix
Imaging, Mississauga, ON, Canada). Three microscopic
fields within SP (stratum pyramidale) and Slm (stratum
lacunosum moleculare) areas in CA3 were selected (mag-
nification of ×40) in MK-stained sections. MK immuno-
reactivity was then measured and expressed as area
density of MK (the fraction of the total given area occu-
pied by MK-positive cells). Three microscopic fields
(magnification at ×40) in CA1, CA3 and hilus region were
counted for Nissl-stained undamaged neurons in each
coronal brain section. Neurons are identified by dark
nucleoli within lightly stained nuclei. GAD67-positive
neurons were quantified in CA1 and CA3 subfields
(strata oriens, radiatum, and pyramidale) and dentate
gyrus layers (dentate hilus, granule cell layer, and molecu-
lar layer). These regions were established according to the
atlas of Paxinos & Watson [36]. Number of Nissl- and
GAD67-positive neurons was expressed as a percentage
of the PBS-injected control sections.Kim et al. BMC Neuroscience 2010, 11:42
http://www.biomedcentral.com/1471-2202/11/42
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Statistical analysis
Data are presented as means SEM. The statistical signifi-
cance was determined by one-way ANOVA and Student-
Newman-Keuls test or Student's t-test using the StatView
program (Abacus Concepts, Berkeley, CA). p  values <
0.05 were considered to be statistically significant.
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